ロード中...
Targeted therapies for myeloproliferative neoplasms
The discovery of JAK2V617F and the demonstration that BCR-ABL-negative myeloproliferative neoplasms (MPNs) are driven by abnormal JAK2 activation have led to advances in diagnostic algorithms, prognosis and ultimately also treatment strategies. The JAK 1/2 inhibitor ruxolitinib was a pivotal moment...
保存先:
| 出版年: | Biomark Res |
|---|---|
| 主要な著者: | , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BioMed Central
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6636147/ https://ncbi.nlm.nih.gov/pubmed/31346467 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40364-019-0166-y |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|